Cyclosporine (CYA) is used to preventing ocular attacks in Behçet's disease patients. Yet there are inter-individual variations in efficacy. In order to analyze the relationship between CYA fluctuation with treatment effectiveness and genetic factors, an association of area under the plasma concentration time at 0-4 hours (AUC0-4) values and polymorphism for multidrug resistance 1 (MDR1) and cytochrome3A5 (CYP3A5) genes was investigated. Genomic DNA was collected from 17 Japanese patients with Behçet's disease. MDR1 polymorphisms were determined by direct sequencing from amplified products for promoter and two exons regions and CYP3A5 polymorphisms were analyzed using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method. AUC0-4 value was determined by the trapezoidal rule from the data of 5 times blood sampling at 0-4 hours. The haplotype 2 in the promoter region of MDR1 influenced significantly lower AUC0-4 values, implying absorption decline of CYA. The CYP3A5 polymorphisms had no direct influence on the effectiveness for CYA treatment. In the relation of CYA and AUC0-4 in the patients, 7 cases were grouped effective and 4 ineffective. Though there was no difference in dosage, the trough values for AUC0-4 were higher in the effective group compared to the ineffective group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701131 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
J Antimicrob Chemother
August 2019
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
Background: Tenofovir monoester is a relatively lipophilic intermediate formed during the hydrolysis of tenofovir disoproxil to tenofovir. Its clinical pharmacokinetic profile and influence on the cellular pharmacology of tenofovir diphosphate have not been reported.
Methods: Plasma, PBMC and dried blood spots (DBS) were obtained from HIV-uninfected adults participating in a randomized, cross-over bioequivalence study of single-dose tenofovir disoproxil fumarate (TDF)/emtricitabine unencapsulated or encapsulated with a Proteus® ingestible sensor.
The utility of trough mycophenolic acid levels for the management of lupus nephritis.
Nephrol Dial Transplant
January 2019
Division of Nephrology, Hypertension and Renal Transplant, Department of Medicine, University of Florida, Gainesville, Florida.
Background: Monitoring of mycophenolic acid (MPA) levels may be useful for effective mycophenolate mofetil (MMF) dosing. However, whether commonly obtained trough levels are an acceptable method of surveillance remains debatable. We hypothesized that trough levels of MPA would be a poor predictor of area under the curve (AUC) for MPA.
View Article and Find Full Text PDFBioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
JAMA Neurol
August 2017
Department of Neurology, University of Cincinnati Medical Center, Cincinnati, Ohio.
Importance: Switching between generic antiepileptic drugs is a highly debated issue that affects both clinical care and overall health care costs.
Objective: To evaluate the single-dose pharmacokinetic bioequivalence of 3 (1 branded and 2 generic drugs) on-market, immediate-release lamotrigine drug products.
Design, Setting, And Participants: The Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy (EQUIGEN) single-dose study is a crossover, prospective, sequence-randomized, replicate pharmacokinetic study conducted at 5 US academic epilepsy centers.
Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.
Int J Chron Obstruct Pulmon Dis
January 2017
Medicine Coordination, Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany.
Purpose: In two trials, the influences of hepatic and renal impairment on the pharmacokinetics of olodaterol, a novel long-acting inhaled β2-agonist for treatment of COPD, were investigated.
Subjects And Methods: The first trial included eight subjects with mild hepatic function impairment (Child-Pugh A), eight subjects with moderate impairment (Child-Pugh B), and 16 matched healthy subjects with normal hepatic function. The second trial included eight subjects with severe renal impairment (creatinine clearance <30 mL·min(-1)) and 14 matched healthy subjects with normal renal function.
Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.
Eur J Drug Metab Pharmacokinet
August 2016
Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Street, 60-781, Poznań, Poland.
We assessed the relations between MPA, free MPA (fMPA) and MPA glucuronide (MPAG) pharmacokinetics and the clinical condition of renal transplant recipients treated with EC-MPS and tacrolimus (Tac) in the first post-transplant year. In 18 adult patients blood samples were collected up to 12 h after EC-MPS oral administration. EC-MPS metabolites' plasma concentrations were determined using validated HPLC methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!